Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 12.02
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Weak growth
Data is available to registered users only
Data is available to registered users only
About
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is neutral on EV/EBITDA.
Data is available to registered users only
Buy
Sell